ATE471383T1 - Promotoren zur expression in modifiziertem vaccinia virus ankara - Google Patents

Promotoren zur expression in modifiziertem vaccinia virus ankara

Info

Publication number: ATE471383T1
Authority: AT; Austria
Prior art keywords: expression; vaccinia virus; promotors; virus ankara; modified vaccinia
Prior art date: 2003-11-24

Application number

AT07014231T

Other languages

English (en)

Inventor

Sonja Leyrer

Original Assignee

Bavarian Nordic As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-24

Filing date

2004-01-17

Publication date

2010-07-15

2004-01-17 Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As

2010-07-15 Application granted granted Critical

2010-07-15 Publication of ATE471383T1 publication Critical patent/ATE471383T1/de

Links

241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 3
241000700618 Vaccinia virus Species 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT07014231T 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara ATE471383T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200301730		2003-11-24

Publications (1)

Publication Number	Publication Date
ATE471383T1 true ATE471383T1 (de)	2010-07-15

Family

ID=34442836

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AT04000943T ATE377088T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT07014231T ATE471383T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression im modifizierten vacciniavirus ankara

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04000943T ATE377088T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AT08008470T ATE504654T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression im modifizierten vacciniavirus ankara

Country Status (18)

Country	Link
US (3)	US7816508B2 (de)
EP (4)	EP1536015B1 (de)
JP (2)	JP2007512009A (de)
KR (1)	KR20060109873A (de)
CN (1)	CN1898390A (de)
AT (4)	ATE377088T1 (de)
AU (1)	AU2004295382A1 (de)
BR (1)	BRPI0416916A (de)
CA (1)	CA2546680A1 (de)
DE (4)	DE602004009743T2 (de)
DK (3)	DK1845164T3 (de)
EA (1)	EA012846B1 (de)
IL (4)	IL174653A0 (de)
NO (1)	NO20062948L (de)
NZ (1)	NZ547405A (de)
SG (2)	SG169325A1 (de)
UA (1)	UA90098C2 (de)
WO (1)	WO2005054484A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU230198B1 (hu) *	2000-11-23	2015-10-28	Bavarian Nordic A/S	Módosított Vacciniavírus Ankara-variáns
DE602004009743T2 (de) *	2003-11-24	2008-08-28	Bavarian Nordic A/S	Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2042604A1 (de) *	2007-09-26	2009-04-01	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	VV-Promotergesteuerte Überexpression von rekombinanten Antigenen
CA2741724C (en) *	2008-11-27	2016-10-04	Bavarian Nordic A/S	Promoters for recombinant viral expression
US8613936B2 (en)	2009-03-13	2013-12-24	Bavarian Nordic A/S	Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) *	2009-03-13	2013-03-12	Bavarian Nordic A/S	Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en)	2010-04-16	2010-06-02	Isis Innovation	Poxvirus expression system
US9173933B2 (en)	2010-10-15	2015-11-03	Bavarian Nordic A/S	Recombinant modified vaccinia virus Ankara influenza vaccine
WO2013083254A1 (en)	2011-12-09	2013-06-13	Bavarian Nordic A/S	Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
DE102013004595A1 (de)	2013-03-15	2014-09-18	Emergent Product Development Germany Gmbh	RSV-Impfstoffe
FR3042121A1 (fr)	2015-10-08	2017-04-14	Jean-Marc Limacher	Composition anti-tumorale
CN106754921A (zh) *	2016-12-12	2017-05-31	孙浩	哺乳动物细胞表达启动子及其制造和使用方法
CN111107872A (zh) *	2017-05-12	2020-05-05	纪念斯隆-凯特林癌症中心	有用于癌症免疫疗法的牛痘病毒突变体
CN121443308A (zh)	2023-03-17	2026-01-30	亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司)	用于治疗乙型肝炎的hbv抗原制剂
WO2025172435A1 (en)	2024-02-13	2025-08-21	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr)	2024-03-13	2025-09-19	Odimma Therapeutics	Vecteur non-viral pour transcription augmentee
FR3171450A1 (fr)	2025-01-17	2026-07-24	Odimma Therapeutics	Virus enveloppé pour la transfection d’acides nucléiques exogènes.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA68327C2 (en)	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
KR100880765B1 (ko)	2000-03-14	2009-02-02	버베리안 노딕 에이/에스	변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
HU230198B1 (hu) *	2000-11-23	2015-10-28	Bavarian Nordic A/S	Módosított Vacciniavírus Ankara-variáns
CN100446812C (zh) *	2001-03-08	2008-12-31	美国国有健康与人类服务部	表达修饰的hiv包膜、gag和pol基因的mva
ES2256747T3 (es)	2002-05-16	2006-07-16	Bavarian Nordic A/S	Expresion de genes en el virus de la vacuna modificado, usando el promotor ati de la viruela de la vaca.
WO2004015118A1 (en) *	2002-08-07	2004-02-19	Bavarian Nordic A/S	Vaccinia virus host range genes to increase the titer of avipoxviruses
DE602004009743T2 (de) *	2003-11-24	2008-08-28	Bavarian Nordic A/S	Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

2004
- 2004-01-17 DE DE602004009743T patent/DE602004009743T2/de not_active Expired - Lifetime
- 2004-01-17 AT AT04000943T patent/ATE377088T1/de active
- 2004-01-17 AT AT07014231T patent/ATE471383T1/de active
- 2004-01-17 DK DK07014231.0T patent/DK1845164T3/da active
- 2004-01-17 DE DE602004027767T patent/DE602004027767D1/de not_active Expired - Lifetime
- 2004-01-17 EP EP04000943A patent/EP1536015B1/de not_active Expired - Lifetime
- 2004-01-17 DK DK04000943T patent/DK1536015T3/da active
- 2004-01-17 EP EP07014231A patent/EP1845164B1/de not_active Expired - Lifetime
- 2004-10-27 CN CNA2004800347488A patent/CN1898390A/zh active Pending
- 2004-10-27 DE DE602004018975T patent/DE602004018975D1/de not_active Expired - Lifetime
- 2004-10-27 AT AT08008470T patent/ATE504654T1/de active
- 2004-10-27 US US10/580,206 patent/US7816508B2/en not_active Expired - Fee Related
- 2004-10-27 JP JP2006540219A patent/JP2007512009A/ja active Pending
- 2004-10-27 BR BRPI0416916-6A patent/BRPI0416916A/pt not_active Application Discontinuation
- 2004-10-27 SG SG201100204-5A patent/SG169325A1/en unknown
- 2004-10-27 KR KR1020067007781A patent/KR20060109873A/ko not_active Ceased
- 2004-10-27 EP EP04790902A patent/EP1689872B1/de not_active Expired - Lifetime
- 2004-10-27 AU AU2004295382A patent/AU2004295382A1/en not_active Abandoned
- 2004-10-27 DE DE602004032187T patent/DE602004032187D1/de not_active Expired - Lifetime
- 2004-10-27 UA UAA200607039A patent/UA90098C2/ru unknown
- 2004-10-27 EP EP08008470A patent/EP1956094B1/de not_active Expired - Lifetime
- 2004-10-27 DK DK04790902T patent/DK1689872T3/da active
- 2004-10-27 AT AT04790902T patent/ATE420191T1/de active
- 2004-10-27 NZ NZ547405A patent/NZ547405A/en unknown
- 2004-10-27 EA EA200601043A patent/EA012846B1/ru not_active IP Right Cessation
- 2004-10-27 CA CA002546680A patent/CA2546680A1/en not_active Abandoned
- 2004-10-27 SG SG200802660-1A patent/SG142300A1/en unknown
- 2004-10-27 WO PCT/EP2004/012125 patent/WO2005054484A1/en not_active Ceased
2006
- 2006-03-30 IL IL174653A patent/IL174653A0/en not_active IP Right Cessation
- 2006-06-23 NO NO20062948A patent/NO20062948L/no not_active Application Discontinuation
2009
- 2009-06-03 IL IL199127A patent/IL199127A/en not_active IP Right Cessation
- 2009-06-03 IL IL199128A patent/IL199128A/en not_active IP Right Cessation
- 2009-06-03 IL IL199126A patent/IL199126A/en not_active IP Right Cessation
2010
- 2010-09-10 US US12/879,101 patent/US20110014242A1/en not_active Abandoned
- 2010-09-10 US US12/879,119 patent/US20110008792A1/en not_active Abandoned
- 2010-12-22 JP JP2010285881A patent/JP2011067219A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
NO20062948L (no)	2006-08-23
ATE420191T1 (de)	2009-01-15
IL174653A0 (en)	2006-08-20
US20110008792A1 (en)	2011-01-13
SG142300A1 (en)	2008-05-28
EP1956094B1 (de)	2011-04-06
EP1845164A3 (de)	2008-03-19
IL199127A (en)	2010-12-30
EP1845164B1 (de)	2010-06-16
US20080112971A1 (en)	2008-05-15
UA90098C2 (en)	2010-04-12
BRPI0416916A (pt)	2007-01-23
DE602004027767D1 (de)	2010-07-29
EP1689872A1 (de)	2006-08-16
KR20060109873A (ko)	2006-10-23
EP1845164A2 (de)	2007-10-17
DE602004009743D1 (de)	2007-12-13
DK1536015T3 (da)	2008-02-18
CN1898390A (zh)	2007-01-17
CA2546680A1 (en)	2005-06-16
ATE377088T1 (de)	2007-11-15
DE602004032187D1 (de)	2011-05-19
EP1956094A1 (de)	2008-08-13
IL199128A (en)	2011-03-31
EP1536015A1 (de)	2005-06-01
WO2005054484A1 (en)	2005-06-16
DE602004018975D1 (de)	2009-02-26
EP1536015B1 (de)	2007-10-31
US20110014242A1 (en)	2011-01-20
DK1689872T3 (da)	2009-04-27
EP1689872B1 (de)	2009-01-07
ATE504654T1 (de)	2011-04-15
DE602004009743T2 (de)	2008-08-28
DK1845164T3 (da)	2010-09-20
IL199126A (en)	2010-12-30
US7816508B2 (en)	2010-10-19
EA200601043A1 (ru)	2006-10-27
EA012846B1 (ru)	2009-12-30
NZ547405A (en)	2008-06-30
JP2011067219A (ja)	2011-04-07
SG169325A1 (en)	2011-03-30
JP2007512009A (ja)	2007-05-17
AU2004295382A1 (en)	2005-06-16

Legal Events

Date

Code

Title

Description

2010-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1845164

Country of ref document: EP

Publication	Publication Date	Title
IL199126A (en)	2010-12-30	Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters.
DK1407033T3 (da)	2006-05-22	Intergeniske områder som insertionssteder i genomet af Modified Vaccinia Virus Ankara (MVA)
DE60332355D1 (de)	2010-06-10	Hla-a24-restringiertes krebsantigenpeptid
UA82998C2 (ru)	2008-06-10	Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
DK1425404T3 (da)	2008-10-06	Vaccinia-MVA-E3L-mutanter og anvendelse deraf
MXPA05005549A (es)	2005-08-16	Virus recombinante de viruela que comprende al menos dos promotores ati de viruela de vaca.
ATE547519T1 (de)	2012-03-15	Gerinnungsfaktor-vii-polypeptide
IL164179A0 (en)	2005-12-18	Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
MX2022015489A (es)	2023-03-22	Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
CY1109244T1 (el)	2014-07-02	Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
WO2005011571A3 (en)	2006-01-05	Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE404219T1 (de)	2008-08-15	Rekombinante poxvirus-calicivirus zusammensetzungen und anwendungen
WO2002077241A3 (en)	2003-01-30	Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
DE50312368D1 (de)	2010-03-11	Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2005001096A8 (en)	2005-08-18	Vaccines against sars
DE60330140D1 (de)	2009-12-31	Gen-silencing-vektor und diesen verwendendes gen-silencing-verfahren
WO2005094415A3 (en)	2007-03-08	Recombinant vectors and methods for inducing an immune response
ATE547530T1 (de)	2012-03-15	Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
WO2003091393A3 (en)	2004-12-09	Nucleic “acid molecules encoding human proteins, and uses thereof”
ATE455863T1 (de)	2010-02-15	Methoden und zusammensetzungen zur identifikation von gen-funktion